Almotriptan
Almotriptan (almotriptan) is a small molecule pharmaceutical. Almotriptan was first approved as Axert on 2001-05-07. It is used to treat migraine disorders in the USA. It is known to target 5-hydroxytryptamine receptor 1B and 5-hydroxytryptamine receptor 1D.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Almotriptan (discontinued: Axert)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Almotriptan malate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AXERT | Johnson & Johnson | N-021001 DISCN | 2001-05-07 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| almotriptan | ANDA | 2023-03-24 |
| almotriptan malate | ANDA | 2017-06-15 |
| axert | New Drug Application | 2012-10-10 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| migraine disorders | EFO_0003821 | D008881 | G43 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
16 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | 2 | 6 | 7 | 15 |
| Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | — | — | 2 | 1 | 3 |
| Headache | D006261 | HP_0002315 | R51 | — | — | — | 2 | — | 2 |
| Migraine with aura | D020325 | EFO_0005295 | G43.1 | — | — | — | 2 | — | 2 |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | — | — | 1 | — | 1 |
| Secondary headache disorders | D051271 | — | — | — | — | — | 1 | — | 1 |
| Prescription drug overuse | D000067490 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | — | 1 | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Almotriptan |
| INN | almotriptan |
| Description | Almotriptan is an indole compound having a 2-(dimethylamino)ethyl group at the 3-position and a (pyrrolidin-1-ylsulfonyl)methyl group at the 5-position. It has a role as a non-steroidal anti-inflammatory drug, a serotonergic agonist and a vasoconstrictor agent. It is a member of indoles, a sulfonamide and a tertiary amine. |
| Classification | Small molecule |
| Drug class | antimigraine agents (5-HT1 receptor agonists); sumatriptan derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12 |
Identifiers
| PDB | — |
| CAS-ID | 154323-57-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1505 |
| ChEBI ID | 520985 |
| PubChem CID | 123606 |
| DrugBank | DB00918 |
| UNII ID | 1O4XL5SN61 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HTR1B
HTR1B
HTR1D
HTR1D
Organism
Homo sapiens
Gene name
HTR1B
Gene synonyms
HTR1DB
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 1B
Protein synonyms
5-HT-1D-beta, 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled, S12, Serotonin 1D beta receptor, Serotonin receptor 1B
Uniprot ID
Mouse ortholog
Htr1b (15551)
5-hydroxytryptamine receptor 1B (P28334)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Almotriptan
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 606 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
599 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use